Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959641 · ClinicalTrials.gov registry record · Phase 2
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
A Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Differentiated Thyroid Gland Carcinoma, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06959641 is a Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Differentiated Thyroid Gland Carcinoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06959641, a Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Differentiated Thyroid Gland Carcinoma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). XL092 is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- OTHER Survey Administration
- PROCEDURE X-Ray Imaging
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-06-06 |
| Est. Completion | 2030-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06959641
The ClinicalTrials.gov registry entry for NCT06959641 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Metastatic Thyroid Gland Oncocytic Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06959641 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06959641 about?
NCT06959641 is a clinical study titled "XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer". This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where ...
What is the current status of trial NCT06959641?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2025-06-06. Estimated completion is 2030-09-11.
What conditions does trial NCT06959641 study?
This clinical trial studies the following conditions: Metastatic Thyroid Gland Oncocytic Carcinoma, Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma.
What interventions are being tested in trial NCT06959641?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Survey Administration (OTHER), X-Ray Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT06959641?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959641 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Thyroid Gland Oncocytic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Thyroid Gland Oncocytic Carcinoma
All registered trials for this condition
Locally Advanced Differentiated Thyroid Gland Carcinoma
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.